Servicio de Microbiología and Unidad de Investigación, Hospital Universitari Son Espases, Palma de Mallorca, Spain.
J Antimicrob Chemother. 2011 Sep;66(9):2022-7. doi: 10.1093/jac/dkr232. Epub 2011 Jun 8.
To investigate the mechanisms of carbapenem resistance in the 175 Pseudomonas aeruginosa isolates (39%; 175/448) showing non-susceptibility (European Committee on Antimicrobial Susceptibility Testing breakpoints) to imipenem (35%), meropenem (33%) and/or doripenem (33%) recovered in 2008-09 from 16 Spanish hospitals during the Comparative Activity of Carbapenem Testing (COMPACT) surveillance study.
MICs (Etest), clonal relatedness (PFGE) and metallo-β-lactamase (MBL) production (Etest-MBL, PCR and sequencing) were determined. Mutation-driven resistance was studied in 60 non-MBL producers according to the doripenem MICs (15 isolates from each of four MIC groups: ≤ 1, 2-4, 8-16 and ≥ 32 mg/L). The expression of ampC, mexB, mexY, mexD and mexF was determined by real-time reverse transcription-PCR and the presence of mutations in oprD by PCR and sequencing. Isogenic mutants expressing combinations of mutation-driven carbapenem resistance were constructed.
Twelve (6.9%) isolates were MBL (VIM-20, VIM-2 or VIM-13) producers and all showed high-level resistance (MIC 32 mg/L) to all three carbapenems. Regarding mutation-driven resistance, all but 1 of the 60 isolates were non-susceptible (MIC >32 mg/L) to imipenem, linked to oprD inactivation. In addition, 50% of the isolates overexpressed ampC, 33% mexY, 32% mexB and 15% mexF, while none overexpressed mexD. Increasing prevalence of ampC overexpression correlated with increasing doripenem MICs (≤ 1, 13%; 2-4, 53%; 8-16, 60%; and ≥ 32, 73%) while overexpression of efflux pumps correlated only with moderate resistance. Doripenem showed slightly higher activity than meropenem against isolates overexpressing ampC, especially mexB or mexY. The analysis of a collection of isogenic laboratory mutants supported this finding.
Although the prevalence of MBL producers is increasing, mutation-driven resistance is still more frequent in Spain. Imipenem resistance was driven by OprD inactivation, while additional AmpC and particularly efflux pump hyperproduction had a lower impact on the activity of doripenem compared with meropenem.
研究在 2008-09 年期间从西班牙 16 家医院的 COMPACT 监测研究中,175 株(39%;175/448)对亚胺培南(35%)、美罗培南(33%)和/或多利培南(33%)表现出非敏感性(欧洲抗菌药物敏感性测试委员会的折点)的 175 株铜绿假单胞菌分离株的碳青霉烯类耐药机制。
测定 MIC(Etest)、克隆相关性(PFGE)和金属β-内酰胺酶(MBL)产生(Etest-MBL、PCR 和测序)。根据多利培南 MIC(每个 MIC 组 15 株,4 个 MIC 组:≤1、2-4、8-16 和≥32mg/L),对 60 株非 MBL 产生株进行了突变驱动的耐药性研究。通过实时逆转录 PCR 测定 ampC、mexB、mexY、mexD 和 mexF 的表达,并通过 PCR 和测序测定 oprD 突变。构建表达突变驱动碳青霉烯类耐药性组合的同基因突变体。
12 株(6.9%)分离株为 MBL(VIM-20、VIM-2 或 VIM-13)产生株,均对所有三种碳青霉烯类药物表现出高水平耐药性(MIC32mg/L)。关于突变驱动的耐药性,除 1 株外,所有 60 株分离株对亚胺培南均不敏感(MIC>32mg/L),这与 oprD 失活有关。此外,50%的分离株过度表达 ampC,33%过度表达 mexY,32%过度表达 mexB,15%过度表达 mexF,而没有分离株过度表达 mexD。随着多利培南 MIC 值的升高(≤1、13%;2-4、53%;8-16、60%;和≥32、73%),ampC 过度表达的发生率逐渐升高,而外排泵的过度表达仅与中度耐药相关。多利培南对过度表达 ampC 的分离株的活性略高于美罗培南,尤其是 mexB 或 mexY。对一组同基因实验室突变体的分析支持了这一发现。
尽管 MBL 产生株的流行率在不断上升,但在西班牙,突变驱动的耐药性仍然更为常见。亚胺培南耐药是由 OprD 失活引起的,而 AmpC 的过度表达,特别是外排泵的过度表达,对多利培南的活性影响小于美罗培南。